pocketful logo
Aurobindo Pharma Ltd logo

Aurobindo Pharma Ltd

NSE: AUROPHARMA BSE: 524804

₹1312.50

(2.07%)

Fri, 20 Mar 2026, 09:25 am

mtf coin illustrationMTF 5x

Aurobindo Pharma Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    72481.14

  • Net Profit

    3483.57

  • P/B

    2.06

  • Sector P/E

    32.08

  • P/E

    19.32

  • EV/EBITDA

    9.39

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    11.15

  • ROCE

    14.16

  • Debt/Equity

    0.24

  • EPS (TTM)

    60.80

  • Dividend Yield

    0

  • Book Value

    603.32

  • Interest Cover

    12.08

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are thoroughly covered by earnings (11.4x coverage).
  • Dividends after 3 years are expected to be thoroughly covered by earnings (12x coverage).
  • Aurobindo Pharma's earnings growth is expected to exceed the low risk savings rate of 7.2%.
  • Aurobindo Pharma's earnings are expected to exceed the low risk growth rate next year.
thumbs up icon

Cons

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Aurobindo Pharma's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Aurobindo Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Cash flow for Aurobindo Pharma is expected to decrease over the next 2 years.
  • Aurobindo Pharma's earnings are expected to grow by 9.7% yearly, however this is not considered high growth (20% yearly).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters51.8251.8251.8251.8251.82
FII13.9414.2114.3715.3316.29
DII27.6827.6026.9326.2325.20
Public6.556.386.876.616.69
Government000.000.000.00

Read More

Technical Analysis

RSI

60.28

MACD

26.29

50 DMA

1197.52

200 DMA

1149.77

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1482.231337.331278.871192.431133.971047.53902.63
Fibonacci1337.331281.981247.791192.431137.081102.891047.53
Camarilla1260.251246.971233.681192.431207.121193.841180.55

Pivots Level: Classic

R3

+289.80

1482.23

R2

+144.90

1337.33

R1

+86.43

1278.87

1192.43
1192.43
Pivot Point
LTP: 1288.20

S1

-58.47

1133.97

S2

-144.90

1047.53

S3

-289.80

902.63

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1268.99

  • 20-EMA

    1248.25

  • 30-EMA

    1233.26

  • 50-EMA

    1215.72

  • 100-EMA

    1192.66

  • 200-EMA

    1177.98

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
09 Feb 2026board-meetingsQuarterly Results, Nine Months Results
05 Nov 2025board-meetingsQuarterly Results
12 Aug 2025agm
04 Aug 2025dividend₹4.00 Dividend /Share08 Aug 2025
08 Jul 2025dividendInterim Dividend - Rs. - 408 Aug 2025
30 Jul 2024agm
26 Jul 2024agmAnnual General Meeting27 Aug 2024
18 Jul 2024buyback
30 Jun 2024buybackBuy Back of Shares30 Jul 2024
10 Feb 2024dividend₹1.50 Dividend /Share20 Feb 2024

Read More

Peer Comparison

Aurobindo Pharma Ltd logo

Aurobindo Pharma Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Lupin Ltd logo

Lupin Ltd

Read More

Aurobindo Pharma Ltd About

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1986

Headquarters

CEO

M R Kumar

Employees

Contact

Website icon

Website

http://www.aurobindo.com

Email icon

Email

cs@aurobindo.com; investorgrievances@aurobindo.com

Phone icon

Phone

91-40-23736370

Location icon

Location

Plot No 2 Maitrivihar, Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, 500038

Read More

Aurobindo Pharma Ltd Company History

YearHistory
2020
  • Tied up with BIRAC to develop COVID-19 vaccine.
  • Collaborated with CSIR to develop COVID-19 vaccine.
  • Signed exclusive licensing agreement with COVAXX.
2021
  • Received USFDA approval for Droxidopa Capsules.
  • Received NCLT approval for scheme of amalgamation.
2022
  • Acquired 51% stake in GLS Pharma Limited.
  • Arm received final USFDA approval for Vasopressin injection.
  • Arm received USFDA approval for Triamcinolone Acetonide injectable suspension.
2023
  • Arm received USFDA approval for cancer drug.
  • To launch HIV triple combination product for children under ViiV Healthcare licence.
2024
  • Received first USFDA approval for Lidocaine Hydrochloride Injection.
  • Commissioned four plants in Andhra Pradesh including Pen-G facility.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
SUNEELA RANI PENAKASell8660510849.307 Oct 2016
THE VANGUARD GROUP INC A/C VANGUARD EMERG. MKTS STOCK INDEBuy2360231875.9419 Sept 2014
M/S MORGAN STANLEY ASIA SINGAPORE PTESell1732500669.9230 May 2014
ABU DHABI INVESTMENT AUTHORUTY - GULABBuy1475687670.5130 May 2014
MACQUARIE BANK LIMITEDSell1940000180.9729 Aug 2013
RELIANCE MUTUAL FUNDBuy1500000172.9924 Feb 2011
MANDATUM INDIA FUNDSell2353228173.0324 Feb 2011
MERRILL LYNCH CAPITAL MARKETS ESPANA S.A SV FCCBSell7038981035.6626 Aug 2010
DEUTSCHE SECURITIES MAURITIUS LTD.Buy3757501037.5326 Aug 2010
BARCLAYS CAPITAL MAURITIUS LTDSell597541851.528 Jan 2010

Read More

Aurobindo Pharma Ltd News

Aurobindo Pharma Unit Gets VAI Rating from USFDA

Aurobindo Pharma's Unit-V of Apitoria Pharma receives VAI classification from USFDA following inspection from December 1-12, 2025, with Form 483 issued containing three observations.

20 Mar 2026

companies

Aurobindo Pharma Gets FDA Form 483 With 9 Observations

US FDA issues Form 483 with 9 observations to Aurobindo Pharma's Eugia Pharma Unit-II facility, designating it as 'Official Action Indicated' following regulatory inspection.

18 Mar 2026

companies

Aurobindo Pharma Gets FDA Form 483 With 9 Observations

US FDA issues Form 483 with 9 observations to Aurobindo Pharma's Eugia Pharma Unit-II facility, designating it as 'Official Action Indicated' following regulatory inspection.

17 Mar 2026

companies

Aurobindo Pharma GST Demand Confirmed by Tax Authority

Principal Commissioner confirms Rs. 77.61 crore GST demand against Aurobindo Pharma for excess IGST refunds and non-compliance issues during 2017-2020. Company plans tribunal appeal.

13 Mar 2026

companies

Aurobindo Pharma Unit Gets FDA VAI Classification

APL Healthcare's Unit-IV receives VAI classification from US FDA after December inspection. Five issues noted during facility review, inspection concluded successfully.

12 Mar 2026

stocks

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800